Source: Eur Respir Rev, 28 (153) 190115; 10.1183/16000617.0115-2019
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
Sergio Harari, Yochai Adir, Marc Humbert. Rare pulmonary disease and orphan drugs: a path to the future. Eur Respir Rev, 28 (153) 190115; 10.1183/16000617.0115-2019

Member's Comments

No comment yet.

Related content which might interest you: Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? Source: Eur Respir Rev 2015; 24: 375-377 Year: 2015 Toward better management of rare and orphan pulmonary diseases Source: Eur Respir J 2016; 47:1334-1335 Year: 2016 Treatment of lymphangioleiomyomatosis: building evidence in orphan diseases Source: Eur Respir J 2014; 43: 966-969 Year: 2014 Rare pulmonary diseases: a common fight Source: Eur Respir Rev, 26 (145) 170059; 10.1183/16000617.0059-2017 Year: 2017 Chronic post-embolic pulmonary hypertension: a new target for medical therapies?}, Source: Eur Respir Rev 2013; 22: 258-264 Year: 2013 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 Rare and orphan lung diseases Source: ISSN=ISSN 1810-6838, ISBN=, page=146 Year: 2005 Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017 Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives Source: Eur Respir J 2005; 26: 984-985 Year: 2005 The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities) Source: International Congress 2014 – Comorbidities Year: 2014 Atypical mycobacteriosis : new drugs, new strategies Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease Year: 2004 A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials Source: Eur Respir J 2015; 46: 243-249 Year: 2015 Combined emphysema & interstitial pulmonary disease. A new disease entity? Source: Eur Respir J 2002; 20: Suppl. 38, 587s Year: 2002 Interstitial lung disease: new challenges and evolving phenotypes Source: Eur Respir Rev 2009; 19: 91-93 Year: 2010 To be or not to be–could it be drug related pulmonary disease? Source: International Congress 2014 – PG02 Current clinical problems in pulmonology Year: 2014 Global effort against rare and orphan diseases Source: Eur Respir Rev 2012 21:171-172 Year: 2012 Global effort against rare and orphan diseases Source: Annual Congress 2013 –European Respiratory Review: what's hot in pulmonary medicine Year: 2013 Chronic thromboembolic pulmonary hypertension: do we need a new definition? Source: Eur Respir J 2014; 44: 1401-1403 Year: 2014